Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When is at 5 cents you'll say, "I should've bought back at 2 cents"...or better yet...never consider this company to be worth only 2 cents, that Stop Loss was a big mistake.
Besides,...there was a rumor about this company taking a deal to sell the company at 3-5 cents, why would any of you sell at anything below that price ?
Educate yourself, but then again...the money is in the disease and not the cure, this company might get paid just to be quiet about it.
You think that a company would be allowed to claim such a discovery without any proof ? They would be shut down immediately.
But it's Ok,..I'll keep my shares....hopefully my profits won't come from your treatment one day.
https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Updates-Report-on-Success-of-Its-NR2F6-Small-Molecule-Antagonist-Screening-Program-for-Treating-Canc?id=203409
Regen BioPharma, Inc. Updates Report on Success of Its NR2F6 Small Molecule Antagonist Screening Program for Treating Cancer
Press Release | 09/11/2018
Regen BioPharma, Inc. Updates Report on Success of Its NR2F6 Small Molecule Antagonist Screening Program for Treating Cancer
PR Newswire
SAN DIEGO, September 11, 2018
SAN DIEGO, September 11, 2018 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently-identified, novel chemical compounds appear to inhibit NR2F6 and thus can potentially be developed for treating cancer.
The NR2F6 nuclear receptor has been identified as a potentially important immune cell inhibitor (an immune checkpoint), which may lead to developing therapies for treating cancers. Therapies that manipulate NR2F6 also show potential to act as cancer stem cell differentiators, transforming cancer stem cells into normal cells.
The NR2F6 program at Regen aims to identify antagonists of NR2F6 in order to unleash the cancer-killing potential of a patient's own immune system as well as identify agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"We have identified a handful of compounds, representing three different structural classes, that inhibit NR2F6 in our primary screening assay," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "They exhibited a dose-dependent inhibitory effect on NR2F6 without cytotoxicity. Our next steps will focus on determining what effect they have on human immune cells."
David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. added, "This is exciting for Regen to reach this point in its goal for developing therapies that treat cancer. These compounds should provide us the basis to further refine our screening for successful antagonists in the development of immunologically-based cancer therapies. "
Correction: Regen BioPharma previously disclosed, in error, that "inhibiting NR2F6 is believed to provide potential therapies for treating autoimmunity." The statement should read: Activating NR2F6 potentially leads to inhibiting the immune system and should lead to therapies for treating autoimmunity diseases such as lupus.
I would never consider a Stop Loss until this is at 10 cents, not too many Apes here sadly. $RGBP
They'll be more upset and this one leaves everyone in the dust. $RGBP
MM's know how to trigger your Stop Loss orders and it's working, some of you won't be there to celebrate with the rest of us...GLTA Longs...$RGBP will have an Epic run soon.
New 8k Out !!
https://www.sec.gov/Archives/edgar/data/0001589150/000160706221000214/rgbp071321form8k.htm
On July 8, 2021 BF Borgers CPA PC (“Borgers”, Regen Biopharma Inc.’s independent registered public accounting firm) began the audit of financial statements for the fiscal year ended September 30, 2020 required to be included in Regen’s Annual Report for the fiscal year ended September 30, 2020 to be filed with the United States Securities and Exchange Commission on Form 10-K.
Regen’s financial statements for the fiscal years ended September 30, 2019 and September 30, 2018 (included in the Company’s Annual report for the fiscal year ended September 30, 2019 filed on Form 10-K) had also been audited by Borgers.
The commencement of this audit of the Company’s financial statements is a further step taken by the Company towards curing the Company’s delinquency with regard to periodic reports required to be filed with the United States Securities and Exchange Commissio
Koos is hard at work, we might become current this week. The SEC has already received the necessary paper work required to become current, is stated in the 8k, no worries here.
https://www.sec.gov/Archives/edgar/data/1589150/000160706221000182/rgbp062821form8k.htm
Item 8.01 Other Events.
Regen Biopharma, Inc. (the “Company”) is in the process of preparing financial statements in order that the Company may have such statements audited (in the case of Annual Financial Statements) and reviewed (in the case of Quarterly Financial Statements). It is intended that the audit and reviews shall be conducted by BF Borgers CPA PC the Company’s independent registered accountant.
On June 21,2021 the Company filed with the United States Securities and Exchange Commission Form its annual report for the fiscal year ended September 30, 2019 on Form 10-K.
Upon completion of the aforementioned audit and reviews the Company intends file the following delinquent periodic reports with United States Securities and Exchange Commission:
Form 10-Q for the quarter ended December 31, 2019
Form 10-Q for the quarter ended March 31, 2020
Form 10-Q for the quarter ended June 30, 2020
Form 10-K for the year ended September 30, 2020
Form 10-Q for the quarter ended December 31, 2020
Watch this video and understand how shorts work and the psychology behind it.
JIM CRAMER EXPOSES CITADEL
Over 130 Mil shares traded between 2 PM and 4 PM, I think we're Golden tomorrow. $RGBP
Margin calls for Melvin tomorrow, hold on to your shares, we riding high $RGBP
Bulls are back in charge, bids are getting trampled. Let's Go back to green and beyond. $RGBP
Weak hands are out, time to fly. $RGBP
Reversal in progress, have some faith. $RGBP
POWER HOUR !! Get Ready for the next run. $RGBP
If anybody here thinks this company and these patents are worth only 2 cents, then by all means cash out now and don't complain.
One thing is for sure, our CEO is a busy bee at work making sure we get true value. $RGBP
Big boys are getting wind of these news and will soon pick this baby up where some of you left off. $RGBP
The following is a list of intellectual property (“IP”) controlled by either Regen Biopharma, Inc. ( the “Company”) or KCL Therapeutics (“KCL”). KCL is a wholly owned subsidiary of the Company.
IP which has been granted patent protection by the United States Patent and Trademark Office (“USPTO”)
GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS)
Provides methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells, which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy.
Patent No: 8263571
METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION
Means, methods, and compositions of matter useful for generation of cancer inhibitory effector cells producing interleukin-17 (IL-17). In one embodiment a cellular population is obtained, said cellular population is exposed to agents capable of inhibiting NR2F6, whereby said inhibition of NR2F6 results in upregulation of IL-17 production, said upregulation of IL-17 production associated with acquisition of anti-tumor activity.
Patent No : 11,053,503
METHODS OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND
Compositions of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor NR2F6 by measuring the ability of a test compound to occupy the active site of NR2F6, in the presence of a reference compound.
Patent No: 10,088,485
MODULATION OF NR2F6 AND METHODS AND USES THEREOF
The application provides methods of modulating NR2F6 in a cell or animal in need thereof by administering an effective amount of a NR2F6 modulator
Patent No: 9091696
2
IP for which a Notice of Allowance has been granted. A Notice of Allowance is notification by the USPTO to the applicant that the USPTO intends to issue a patent
ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES
Antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
Application Number: 15/162,370
IP for which Patent Protection has expired due to non payment of fees for which revival is in process:
METHOD OF CANCER TREATMENT USING SIRNA SILENCING
Comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.
Patent No: 8389708
IP for which a Notice of Allowance was granted but classified as abandoned by the USPTO. Revival in progress.
UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS
Compositions of matters, cells, and treatment protocols useful for induction of anticancer responses in a patient suffering from cancer. In one embodiment the invention provides the use of NR2F6 silencing or gene editing in cord blood cells possessing anti-tumor activity in order to induce potentiated killer cells suitable for therapeutic use. In one embodiment said allogeneic cord blood killer cells are administered to initiate a cascade of antitumor immune responses, with initially responses mediated by allogeneic killer cells, and followed by endogenous immune responses.
Application Number: 15/494,358
Active Patent Applications:
ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL;
Application Number 17035955.
REDUCTION OF POST-SURGERY CANCER METASTASIS BY COMBINATION OF CANNABIDIOL AND NR2F6 INHIBITION.
Application Number 17037284
SUPPRESSION OF PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF NR2F6
Application Number 17087386
STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY
Application Number 17010720
3
SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN HUMANS
Application Number 15820324
SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY.
Application Number 15364111
Patent issued to Zander Therapeutics, Inc. derived from intellectual property licensed by Zander Therapeutics Inc. from KCL.
CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES
Compositions of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in vitro, and re-administering said immunocytes into a patient in need of therapy. In one embodiment, immunocytes expanded are T cells possessing tumor cytotoxic activity induced by stimulation of NKG2D.
Patent Number: 10,030,227
4
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGEN BIOPHARMA, INC.
Dated: July 13, 2021 By: /s/ David Koos
David Koos
Chief Executive Officer
Same here, you can't afford to flip a company like this, I might wake up one day and have to buy back at 50 cents, I'm Ok, I'll leave these shares to my kids, this company will be on Nasdaq soon.
Ridiculous statement, Koos is the reason is going up, speak to Melvin if you want. This company has not sold a single share.
Koos knows what this stock is worth....and sure as hell is not 2 cents. LMFAO
I'll be damned if I sell this stock at 2 cents only. $RGBP
Shortie is trying hard to cover, let it rip. $RGBP
I love this stock, hold on fellas, this week will be epic. $RGBP
These shorts will get so burned soon. Melvin is still at it, when will Melvin learn ?
$RGBP is starting to look good despite low volume day.
So you think the CEO of McDonalds knows how to flip burgers ?
He already filled the paper work with the SEC, what are you babbling about ?
That's the reason we are not in the Grey market, because it's already taken care of.
Not for much longer, WSB will put them out of business soon.
I think they are buying more, I know I am.
Clean the swamp, good job.
They were awarded shares in 2015, it's 2021, that's 6 years later, I'm sure they sold their shares long ago, it's in our hands now, and if they didn't yet, that means they are worth way more as they are waiting for dollars and not pennies.
Considering that the float is over 3 Bil, we the shareholders control the float completely by now.
Why sell ? This is the time to hold.
$RGBP
No other explanation, the share structure hasn't changed and we all doubled our positions since 8 cents,..so yes they are in here deep, and they will leave broke soon...we own shares, they own imaginary shares.
$RGBP
Nice push today, accumulation was very nice and a bullish trend is forming. $RGBP
When $RGBP looks down and out is when it takes off, Long and Strong.
Not low volume at all, 50 mil shares at above 2 cents, over $1 Mil dollar volume, that's not low by any standards.
$RGBP
Flippers are buyers, are they not ? Soon they'll flip themselves out, keep the stock circulating and fresh, volume is volume however you spell it...it creates a market and liquidity.
Flippers are welcome.
$RGBP
I hope that Koos is smart enough to offer a private offering at 10 cents or above, to raise $1 mil first and then our price will adjust accordingly.
$RGBP
Cause he's a shareholder now...he played us all. $RGBP
Weak hands are out, time to ride past 3 cents and hold the line....the night is young and so am I. $RGBP